Italy's Chiesi eyes Russian expansion
Privately held Italian drugmaker Chiesi Farmaceutici is considering a massive expansion into the Russian pharmaceutical market, through the launch of a full cycle of production of its flagship drugs for the treatment of bronchial allergy and pulmonary disease at the production facilities of local drugmaker Pharmstandard by 2015.
It is planned that the production will be initiated by Pharmstandard-Leksredstva in the city of Kursk, where the company already carries out secondary packaging of its drugs such as Atimos (formoterol), Klenil Jet (beclomethasone), Budieyr (budesonide) and Foster (formoterol beclomethasone).
Aims to become major supplier of pulmonary medicines in Russia
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze